Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
Exercise improved QoL, functioning in breast cancer survivors
BARCELONA – A supervised and adapted exercise program improved quality of life, physical functioning, and strength in breast cancer survivors...
News
Better overall survival with nivolumab vs. chemo for advanced ESCC
BARCELONA –Nivolumab was associated with improved overall survival and a favorable safety profile vs. chemotherapy...
News
Nivolumab benefit for NSCLC persists at 5-year follow-up
BARCELONA – Nivolumab, compared with docetaxel chemotherapy, led to a fivefold improvement in 5-year overall...
News
Immune checkpoint inhibition in SCLC: Modest outcomes, many questions
Immune checkpoint inhibitors have activity in SCLC, but achieving more durable disease control and better survival requires greater understanding...
News
New data further define role of PD-L1 status, immunotherapy in metastatic breast cancer
BARCELONA – PD-L1 status in mTNBC or HER2+ breast cancer appears to identify distinct disease entities with varying likelihood of benefit from...
News
Consider renal function in TLS risk assessment of venetoclax-treated CLL
EDINBURGH – Impaired renal function may indicate excess risk of tumor lysis syndrome (TLS) in venetoclax-treated...
News
Soccer pros may face increased risk of death from neurodegenerative disease
Mortality associated with neurodegenerative disease was higher, and mortality associated with other causes lower, among former pro soccer players...
News
Adding veliparib to chemotherapy improves PFS in BRCA-mutated breast cancer
BARCELONA – Adding veliparib to chemotherapy improved PFS and provided more durable benefit than did chemotherapy...
News
Veliparib improves PFS in high-grade serous epithelial ovarian cancer
BARCELONA – Adding veliparib to frontline CT and maintenance significantly extended PFS in women with high-grade...
News
PJP prophylaxis may be unnecessary for CLL patients on BTK inhibitors
EDINBURGH – The findings show an overall low pneumocystis jiroveci pneumonia prevalence in patients not receiving prophylaxis.
News
Nivolumab boosts overall survival in HCC
BARCELONA – Nivolumab led to clinically meaningful, but not statistically significant, improvement in OS and ORR vs. sorafenib for first-line...
News
PRIMA study: Niraparib maintenance improves PFS in advanced OC
BARCELONA – Niraparib improves PFS when given after first-line chemotherapy for advanced ovarian cancer, according...
News
mIDH1 inhibitor ivosidenib improves progression-free survival in advanced cholangiocarcinoma
BARCELONA - The first-in-class oral inhibitor of mIDH1, significantly improved PFS for advanced cholangiocarcinoma in the global, randomized,...
News
MONARCH 2: Abemaciclib plus fulvestrant improves overall survival
BARCELONA – MONARCH 2 trial data show that adding the CDK4/6 inhibitor abemaciclib to fulvestrant significantly improves overall survival in HR+,...